$8m is now my baseline for FY20 (assuming 30% tax rate and no tax asset inclusion), and that's a low baseline given production increases and progress of Alusion sales.
I noticed management were careful when talking about the 2200T capacity. They didn't say it's in excess of current demand - rather, they said it's in excess of "current order intake". Very big difference.
Given how conservative this bunch are, $12m NPAT for FY20 is not unreasonable in the least (again, assumes a full 30% tax and no tax asset realisation, nor R&D benefits). It also doesn't include any benefits from the reduction in 24/7 shift work and the spike in wages as a result.
And correct me if I'm wrong, but Merck might be paying a decent sum of money in FY22 if they want to continue with Alusion exclusivity...
As for the remaining IP - if even 1 in that list works, it's just icing on the cake.
- Forums
- ASX - By Stock
- ANO
- Ann: ANO Investor Presentation Update
Ann: ANO Investor Presentation Update, page-5
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ANO (ASX) to my watchlist
(20min delay)
|
|||||
Last
72.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.96M |
Open | High | Low | Value | Volume |
72.0¢ | 72.0¢ | 72.0¢ | $396 | 550 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15322 | 72.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
76.0¢ | 480 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15322 | 0.720 |
1 | 425 | 0.705 |
1 | 455 | 0.655 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.760 | 480 | 1 |
0.790 | 500 | 1 |
0.800 | 26001 | 1 |
1.050 | 15000 | 1 |
0.000 | 0 | 0 |
Last trade - 12.20pm 25/07/2024 (20 minute delay) ? |
Featured News
ANO (ASX) Chart |